Cell Therapy Human Raw Materials Market Size to Reach USD 18.1 Billion by 2032 Due to Increased Focus on Cell-Based Therapies – SNS Insider

Cell Therapy Human Raw Materials Market growth is Driven by Rising Demand for Advanced Cell Culture Media and Therapeutic Applications.

Austin, May 28, 2025 (GLOBE NEWSWIRE) -- According to SNS Insider, The Cell Therapy Human Raw Materials Market was valued at USD 2.9 billion in 2023 and is projected to reach USD 18.1 billion by 2032, growing at an impressive CAGR of 22.6% from 2024 to 2032. This remarkable growth is driven by the increasing demand for cell-based therapies across various medical applications and the need for high-quality raw materials to support cell culture, growth, and therapeutic efficacy.

Get a Sample Report of Cell Therapy Human Raw Materials Market@ https://www.snsinsider.com/sample-request/4487

Market Overview

The Cell Therapy Human Raw Materials Market is experiencing significant growth due to the increasing demand for cell-based therapies such as stem cell therapy, regenerative medicine, and CAR-T cell therapy. With advancements in biotechnology, the need for high-quality raw materials, including cell culture media, growth factors, and cryopreservation reagents, has surged. The supply chain for these materials is expanding, with leading biotechnology companies and research institutions investing heavily in R&D and production capabilities.

The rising focus on personalized medicine and gene editing technologies is further propelling the demand for specialized raw materials. Companies are working to ensure a stable supply of critical components, while regulatory bodies emphasize the safety and efficacy of these materials. The growing number of clinical trials and commercialization efforts in cell therapy applications is driving both demand and supply in the market.

Major Players Analysis Listed in this Report are:

• Thermo Fisher Scientific .
• Lonza Group AG
• Miltenyi Biotec GmbH
• Stemcell Technologies Inc.
• Bio-Techne Corporation
• BD Biosciences
• GE Healthcare Life Sciences
• Macopharma
• NantCell Inc.
• CellGenix GmbH and other key players

Cell Therapy Human Raw Materials Market Report Scope

Segment Analysis

By Product:

The Cell Culture Media segment dominated the market in 2023, accounting for about 40% of the market share. This segment is crucial for cell therapy applications as it provides the necessary environment for cell growth, differentiation, and functionality. The increasing demand for advanced and specialized media, particularly for therapies like stem cell and CAR-T cell therapy, drives the growth of this segment. Companies are focusing on developing media formulations tailored to specific cell types, ensuring optimal therapeutic outcomes.

By End-Use:

The Biotechnology & Pharmaceutical Companies segment held the largest market share, estimated at 55% in 2023. These companies are heavily investing in the development and commercialization of cell-based therapies, driving the demand for high-quality raw materials. With significant investments in gene editing, regenerative medicine, and other cutting-edge therapies, the need for reliable and specialized raw materials is critical for research, clinical trials, and large-scale production.

Cell Therapy Human Raw Materials Market Segmentation

By Product

• Cell Culture Media
• Cell Culture Sera
• Cell Culture Supplements
• Proteins
  • Growth Factors
  • Nucleotides
  • Others
• Reagents & Buffers
• Others

By End-Use

• Biotechnology & Pharmaceutical Companies
• CROs & CMOs
• Academic & Research Institutions
• Hospitals & Clinics

Regional Analysis

North America dominated the Cell Therapy Human Raw Materials Market in 2023, accounting for a significant market share. The region's growth is attributed to the presence of major biotechnology companies, advanced research facilities, and substantial government funding for cell therapy research. The U.S., in particular, is at the forefront of innovations in regenerative medicine and gene therapies, with companies like  Novartis  and  Gilead Sciences  leading the market. The high adoption of cell-based therapies, combined with strong regulatory support, positions North America as the dominant region.

Asia Pacific is expected to be the fastest-growing region during the forecast period. Countries such as China, Japan, and South Korea are making substantial investments in biotechnology and cell therapy research. The region is witnessing a surge in clinical trials and government initiatives supporting regenerative medicine. Companies like Takeda Pharmaceuticals and Samsung Biologics are expanding their production capabilities, contributing to the rapid growth of the market in Asia Pacific.

Buy a Single-User PDF of Cell Therapy Human Raw Materials Market Analysis & Outlook Report 2024-2032@ https://www.snsinsider.com/checkout/4487

Recent Developments

• February 2024:  Thermo Fisher Scientific expanded its cell culture media portfolio with specialized formulations for gene and cell therapy research.
• March 2024:  Lonza Group announced the launch of a new cryopreservation reagent designed to improve the viability and recovery of cells post-thawing in cell-based therapies.
• April 2024:  Sartorius launched a single-use bioreactor system aimed at streamlining the production of cell therapy raw materials in large-scale manufacturing processes.

Key Takeaways

• The global Cell Therapy Human Raw Materials Market is expected to grow at a CAGR of 22.6% from 2024 to 2032, driven by increasing demand for cell-based therapies.
• Cell Culture Media holds the largest market share, with significant growth potential due to its critical role in cell therapy applications.
• Biotechnology & Pharmaceutical Companies dominate the end-use segment, accounting for 55% of the market share, owing to their large-scale investments in cell therapy research and development.
• North America leads the market with advanced infrastructure and strong regulatory support, while Asia Pacific is poised to be the fastest-growing region due to rising investments and clinical trials.
• Recent developments in the market include new product launches aimed at improving cell therapy efficiency and scalability, particularly in CAR-T and stem cell therapies.

Table of Contents – Major Key Points

1. Introduction

2. Executive Summary

3. Research Methodology

4. Market Dynamics Impact Analysis

5. Statistical Insights and Trends Reporting

6. Competitive Landscape

7. Cell Therapy Human Raw Materials Market by Product

8. Cell Therapy Human Raw Materials Market by End-Use

9. Regional Analysis

10. Company Profiles

11. Use Cases and Best Practices

12. Conclusion

Related Reports

Global Cell Therapy Market to Soar to $28.98 Billion by 2032, Driven by 22.55% CAGR Through 2024–2032.

Regenerative Medicine Market Forecasts Explosive Growth, Projected to Hit $235.98 Billion by 2032 at 24.66% CAGR.

Stem Cell Therapy Market Set to Reach $1.11 Billion by 2032, Growing at 17.10% CAGR.

About Us:

SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.

CONTACT: Contact Us:
Jagney Dave - Vice President of Client Engagement
Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)